The US health regulator has provided its approval to the drug firm Wockhardt for the generic Olopatadine HCI eye drops that are used in treating opthalmic allergies.

Wockhardt has said in a BSE filing that the company has received final approval from the United States Food and Drug Administration (USFDA) for Olopatadine HCI 0.1 percent opthalmic solution.

It added that the product is a generic version of Patanol, which is marketed in the US by Alcon, a subsidiary of pharma major Novartis.

Read EquityPandit’s Technical Analysis on Nifty Pharma